Table 3.
Association Between Cabergoline and Cardiac Complications: Unmatched Analysis
| Unadjusted | Adjusted | |||
|---|---|---|---|---|
| RR (95% CI) | P value | RR (95% CI) | P value | |
| Cabergoline use | ||||
| No | 1 (ref) | - | 1 (ref) | - |
| Yes | 1.43 (0.84-2.42) | 0.189 | 0.98 (0.60-1.60)a | 0.922 |
| Cumulative cabergoline dose (per 100mg) | 1.02 (0.98-1.07) | 0.379 | 0.96 (0.81-1.14)b | 0.628 |
| Quartiles of cabergoline dose | ||||
| Quartile 1 (<27.0 mg) | 1 (ref) | - | 1 (ref) | - |
| Quartile 2 (27.1-56.1 mg) | 0.50 (0.09-2.71) | 0.424 | 0.45 (0.08-2.42)b | 0.350 |
| Quartile 3 (56.2-122.9 mg) | 1.25 (0.34-4.58) | 0.736 | 0.57 (0.15-2.12)b | 0.402 |
| Quartile 4 (>123.0 mg) | 1.76 (0.53-5.90) | 0.359 | 0.59 (0.16-2.15)b | 0.422 |
| Duration of cabergoline use (per month) | 1.00 (1.00-1.01) | 0.341 | 0.99 (0.98-1.00)b | 0.107 |
| Quartiles of duration of cabergoline use | ||||
| Quartile 1 (6-14.5 months) | 1 (ref) | - | 1 (ref) | - |
| Quartile 2 (14.6-26.6 months) | 0.80 (0.22-2.95) | 0.743 | 0.66 (0.19-2.31)b | 0.511 |
| Quartile 3 (26.7-46.4 months) | 0.60 (0.15-2.47) | 0.479 | 0.39 (0.10-1.55)b | 0.182 |
| Quartile 4 (>46.4) | 1.21 (0.38-3.88) | 0.752 | 0.27 (0.06-1.13)b | 0.072 |
a Adjusted for age, diabetes, Black or Black British ethnicity, gender, hypertension, Newham CCG
b Adjusted for age, diabetes, hypertension